145 related articles for article (PubMed ID: 30475580)
1. Impact on Glioblastoma U87 Cell Gene Expression of a Carborane Cluster-Bearing Amino Acid: Implications for Carborane Toxicity in Mammalian Cells.
He T; Chittur SV; Musah RA
ACS Chem Neurosci; 2019 Mar; 10(3):1524-1534. PubMed ID: 30475580
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of the boronated porphyrin TABP-1 in U-87 MG intracerebral human glioblastoma xenografts.
Ozawa T; Santos RA; Lamborn KR; Bauer WF; Koo MS; Kahl SB; Deen DF
Mol Pharm; 2004; 1(5):368-74. PubMed ID: 16026007
[TBL] [Abstract][Full Text] [Related]
3. Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer.
Couto M; Alamón C; Nievas S; Perona M; Dagrosa MA; Teixidor F; Cabral P; Viñas C; Cerecetto H
Chemistry; 2020 Nov; 26(63):14335-14340. PubMed ID: 32738078
[TBL] [Abstract][Full Text] [Related]
4. Towards carborane-functionalised structures for the treatment of brain cancer.
Calabrese G; Daou A; Barbu E; Tsibouklis J
Drug Discov Today; 2018 Jan; 23(1):63-75. PubMed ID: 28886331
[TBL] [Abstract][Full Text] [Related]
5. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.
Chadha M; Capala J; Coderre JA; Elowitz EH; Iwai J; Joel DD; Liu HB; Wielopolski L; Chanana AD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):829-34. PubMed ID: 9531367
[TBL] [Abstract][Full Text] [Related]
6. Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies.
Turkez H; Arslan ME; Tatar A; Mardinoglu A
Neurochem Int; 2021 Oct; 149():105137. PubMed ID: 34293392
[TBL] [Abstract][Full Text] [Related]
7. Boron's neurophysiological effects and tumoricidal activity on glioblastoma cells with implications for clinical treatment.
Altinoz MA; Topcu G; Elmaci İ
Int J Neurosci; 2019 Oct; 129(10):963-977. PubMed ID: 30885023
[No Abstract] [Full Text] [Related]
8. Boron neutron capture therapy of brain tumors: past history, current status, and future potential.
Barth RF; Soloway AH; Brugger RM
Cancer Invest; 1996; 14(6):534-50. PubMed ID: 8951358
[TBL] [Abstract][Full Text] [Related]
9. Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy.
Wu G; Barth RF; Yang W; Lee RJ; Tjarks W; Backer MV; Backer JM
Anticancer Agents Med Chem; 2006 Mar; 6(2):167-84. PubMed ID: 16529539
[TBL] [Abstract][Full Text] [Related]
10. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
11. Carborane-Containing Folic Acid
Gruzdev DA; Telegina AA; Levit GL; Solovieva OI; Gusel'nikova TY; Razumov IA; Krasnov VP; Charushin VN
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430206
[TBL] [Abstract][Full Text] [Related]
12. N(4)-[B-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan)methyl]-2'-deoxycytidine as a potential boron delivery agent with respect to glioblastoma.
Uram Ł; Nizioł J; Maj P; Sobich J; Rode W; Ruman T
Biomed Pharmacother; 2017 Nov; 95():749-755. PubMed ID: 28888921
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.
Harvey KA; Xu Z; Saaddatzadeh MR; Wang H; Pollok K; Cohen-Gadol AA; Siddiqui RA
J Neurosurg; 2015 Mar; 122(3):547-56. PubMed ID: 25526274
[TBL] [Abstract][Full Text] [Related]
14. Boron neutron capture therapy of primary and metastatic brain tumors.
Barth RF; Soloway AH
Mol Chem Neuropathol; 1994; 21(2-3):139-54. PubMed ID: 8086033
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-decorated carborane-TAT conjugation nanomicelles: A potential boron agent with enhanced selectivity of tumor cellular uptake.
Quan H; Fan L; Huang Y; Xia X; He Y; Liu S; Yu J
Colloids Surf B Biointerfaces; 2021 Aug; 204():111826. PubMed ID: 33984611
[TBL] [Abstract][Full Text] [Related]
16. Boron neutron capture therapy of cancer: current status and future prospects.
Barth RF; Coderre JA; Vicente MG; Blue TE
Clin Cancer Res; 2005 Jun; 11(11):3987-4002. PubMed ID: 15930333
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of carborane-containing porphyrins as tumour targeting agents for boron neutron capture therapy.
Miura M; Micca PL; Fisher CD; Gordon CR; Heinrichs JC; Slatkin DN
Br J Radiol; 1998 Jul; 71(847):773-81. PubMed ID: 9771389
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization and biological evaluation of carboranylmethylbenzo[b]acridones as novel agents for boron neutron capture therapy.
da Silva AF; Seixas RS; Silva AM; Coimbra J; Fernandes AC; Santos JP; Matos A; Rino J; Santos I; Marques F
Org Biomol Chem; 2014 Jul; 12(28):5201-11. PubMed ID: 24915168
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution of a carborane-containing porphyrin as a targeting agent for Boron Neutron Capture Therapy of oral cancer in the hamster cheek pouch.
Kreimann EL; Miura M; Itoiz ME; Heber E; Garavaglia RN; Batistoni D; Rebagliati RJ; Roberti MJ; Micca PL; Coderre JA; Schwint AE
Arch Oral Biol; 2003 Mar; 48(3):223-32. PubMed ID: 12648560
[TBL] [Abstract][Full Text] [Related]
20. Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy.
Wada Y; Hirose K; Harada T; Sato M; Watanabe T; Anbai A; Hashimoto M; Takai Y
J Radiat Res; 2018 Mar; 59(2):122-128. PubMed ID: 29315429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
